Efficacy of Dose-Adjusted Regimen on Survival in Frail Adults With Acute Lymphoblastic Leukemia

NCT07258043 · clinicaltrials.gov ↗

RECRUITING

Status

45

Enrollment

OTHER_GOV

Sponsor class

Conditions

Acute Lymphobkastic Leukemia
Leukemia
Overall Survival

Interventions

DRUG: Patients meeting criteria will receive DA-EPOCH via central line for 5 days every 21 days, with monitoring, supportive care, transfusions, prophylaxis, and G-CSF for 5 doses per cycle

Sponsor

Hospital General de Mexico